Is vaccine prices justifiable, asks Congress leader Chidambaram

Congress leader P. Chidambaram has slammed the government over prices of vaccines

P Chidambaram
Senior Congress leader P Chidambaram. Photo: PTI
IANS New Delhi
1 min read Last Updated : Apr 25 2021 | 12:20 PM IST

Congress leader P. Chidambaram has slammed the government over prices of vaccines, and asked why the government is not invoking compulsary licensing.

The former finance minister said in a tweet, "Will those who justified the Covisheld prices of Rs 400 and 600 also justify the Covaxin prices of Rs 600 and 1200 announced today?"

"The government is standing (not helplessly) and silently endorsing the blatant profiteering and exploitation by the two manufacturers. Why is the government not invoking the provision of 'compulsory licensing'?" He said in another tweet.

Bharat Biotech has said its Covaxin will cost Rs 600 for state governments and Rs 1,200 for private hospitals, while the other vaccine maker, Serum Institute of India (SII), has said it will sell its Covishield developed by Oxford-AstraZeneca at Rs 400 a jab to states and Rs 600 to private hospitals.

Several chief ministers have raised red flag over the different pricing of vaccines and have asked for uniform pricing for all.

--IANS

miz/skp/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 25 2021 | 12:15 PM IST

Next Story